Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GlutaPanc: L-glutamine with Gemcitabine/Nab-paclitaxel in Pancreatic Cancer
NCT04634539Phase 1Completed
- Start
- May 2021
- Primary completion
- Jul 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of glutamine in pancreatic cancer (PC). Primary endpoint: Recommended Phase II Dose at 4 weeks. Started May 2021; status: completed.
02
Drugs
glutamine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04634539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04634539.